REC617- Recombinant trivalent influenza virus vaccine

Influenza virus is the leading causative pathogen of respiratory disease. We are developing REC617, a recombinant trivalent influenza virus vaccine, that is designed with rapid and efficient expression of protective antigens and takes full advantage of the immune-enhancing effects of adjuvants.